ALZN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALZN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
For the three months ended in Jan. 2024, Alzamend Neuro spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Alzamend Neuro gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Jan. 2024.
The historical data trend for Alzamend Neuro's Cash Flow from Investing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro Annual Data | |||||||||||
Trend | Apr19 | Apr20 | Apr21 | Apr22 | Apr23 | ||||||
Cash Flow from Investing | 0.23 | 0.11 | 0.10 | -0.11 | - |
Alzamend Neuro Quarterly Data | ||||||||||||||||||
Apr19 | Jan20 | Apr20 | Jul20 | Oct20 | Jan21 | Apr21 | Jul21 | Oct21 | Jan22 | Apr22 | Jul22 | Oct22 | Jan23 | Apr23 | Jul23 | Oct23 | Jan24 | |
Cash Flow from Investing | Get a 7-Day Free Trial | - | - | -0.15 | - | - |
Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).
If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).
Likewise, if a company buys another company for cash, this will reduce their cash position.
Alzamend Neuro's Cash Flow from Investing for the fiscal year that ended in Apr. 2023 is calculated as:
Alzamend Neuro's Cash Flow from Investing for the quarter that ended in Jan. 2024 is calculated as:
Cash Flow from Investing for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alzamend Neuro (NAS:ALZN) Cash Flow from Investing Explanation
Cash flow from investing contains nine items:
1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.
Alzamend Neuro's purchase of property, plant, equipment for the three months ended in Jan. 2024 was $0.00 Mil. It means Alzamend Neuro spent $0.00 Mil on purchasing property, plant, equipment.
In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.
In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.
Alzamend Neuro's sale of property, plant, equipment for the three months ended in Jan. 2024 was $0.00 Mil. It means Alzamend Neuro gained $0.00 Mil from selling property, plant, and equipment.
3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.
Alzamend Neuro's purchase of business for the three months ended in Jan. 2024 was $0.00 Mil. It means Alzamend Neuro spent $0.00 Mil on purchasing business.
4. Sale Of Business:
Sale of business indicates the amount gained from selling business.
Alzamend Neuro's sale of business for the three months ended in Jan. 2024 was $0.00 Mil. It means Alzamend Neuro gained $0.00 Mil from selling business.
5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.
Alzamend Neuro's purchase of investment for the three months ended in Jan. 2024 was $0.00 Mil. It means Alzamend Neuro spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.
6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.
Alzamend Neuro's sale of investment for the three months ended in Jan. 2024 was $0.00 Mil. It means Alzamend Neuro gained $0.00 Mil from selling investments.
7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.
Alzamend Neuro's net Intangibles purchase and sale for the three months ended in Jan. 2024 was $0.00 Mil. It means Alzamend Neuro paid $0.00 Mil for net Intangibles purchase and sale.
8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.
Alzamend Neuro's cash from discontinued investing activities for the three months ended in Jan. 2024 was 0.00 Mil. It means Alzamend Neuro paid $0.00 Mil for discontinued investing activities.
9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.
Alzamend Neuro's cash from other investing activities for the three months ended in Jan. 2024 was $0.00 Mil. It means Alzamend Neuro paid $0.00 Mil for other investing activities.
Thank you for viewing the detailed overview of Alzamend Neuro's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.
Ault Milton C Iii | 10 percent owner | 11411 SOUTHERN HIGHLANDS PARKWAY, SUITE 240, LAS VEGAS NV 89141 |
David J Katzoff | officer: Chief Operating Officer | 201 SHIPYARD WAY, NEWPORT BEACH CA 92663 |
Stephan Jackman | director, officer: Chief Executive Officer | C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
Lynne Fahey Mcgrath | director | 28145 CEDAR POINT RD., EASTON MD 21601 |
Mark Gustafson | director | 10691 ROSECROFT CRESCENT, RICHMOND A1 V7A 2H9 |
William B. Horne | director | C/O AULT ALLIANCE, INC., 940 SOUTH COAST DRIVE, SUITE 200, COSTA MESA CA 92626 |
Henry Carl Nisser | director, officer: Exec VP and General Counsel | 100 PARK AVENUE, SUITE 1658A, NEW YORK NY 10017 |
Kenneth S Cragun | officer: SVP of Finance | 3775 CHIPPEWA CIRCLE, CORONA CA 92881 |
Jeffrey Oram | director | 15 ORCHARD STREET, MENDHAM NJ 07945 |
Escalona Lien | officer: Chief Financial Officer | C/O ALZAMEND NEURO, INC., 3802 SPECTRUM BOULEVARD, SUITE 112C, TAMPA FL 33612 |
Andrew H. Woo | director | 2021 SANTA MONICA BLVD., SUITE 525E, SANTA MONICA CA 90404 |
From GuruFocus
By Business Wire Business Wire • 11-15-2022
By Business Wire Business Wire • 06-03-2022
By Business Wire • 12-11-2023
By Business Wire Business Wire • 05-17-2022
By Business Wire Business Wire • 04-28-2022
By Business Wire Business Wire • 10-31-2022
By Business Wire • 09-22-2023
By Business Wire Business Wire • 12-28-2022
By PRNewswire PRNewswire • 12-15-2021
By Business Wire Business Wire • 01-04-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.